We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Groundbreaking 2-In-1 Procedure Combines C-Section and Ovarian Cancer Surgery

By HospiMedica International staff writers
Posted on 12 Jan 2024

Women carrying BRCA1 or BRCA2 gene mutations face a significantly higher lifetime risk of developing ovarian cancer, estimated between 11-68%, compared to about 2% in the general population. More...

Approximately 15% of ovarian cancers are associated with these genetic alterations. Bilateral salpingo-oophorectomy (RRSO), a preventive surgery to remove the fallopian tubes and ovaries, is currently the only confirmed method to substantially lower the mortality risk from ovarian cancer, reducing the likelihood of developing the disease by at least 95%. In a pioneering approach, four women, all carriers of BRCA1 or BRCA2 gene mutations and scheduled for cesarean sections, underwent a combined procedure where they delivered their babies via cesarean and simultaneously had RRSO to reduce their ovarian cancer risk. Post-surgery, all four women expressed high satisfaction with the two-in-one procedure.

This innovative approach adopted by the team at University College London (UCL, London, UK), offers a viable option for women carrying BRCA gene mutations who are undergoing cesarean sections. The four patients, aged between 40 and 45, were BRCA1 or BRCA2 gene carriers and chose cesarean delivery for reasons unrelated to their genetic risk, with no plans for more children. The surgeries were successful without any major postoperative complications, and the hospital stays were no longer than what is typical for cesarean sections alone. Although there was a theoretical risk of increased blood loss due to the combined surgery, there was no such issue in these cases. It is important to note that RRSO invariably leads to infertility. However, women who have previously harvested eggs may still pursue assisted reproductive techniques. Additionally, RRSO induces early menopause, making hormone replacement therapy advisable until the age of 51, barring contraindications like a history of breast cancer treatment.

“Offering this two-in-one surgery could prove very beneficial to other women at high risk of ovarian cancer, who would then avoid the need for separate risk-reducing surgery,” said Professor Adam Rosenthal, consultant gynecologist at UCLH. “The number of women who give birth by cesarean section is increasing around the world, as is the number of women who know they carry a gene alteration which increases their ovarian cancer risk. This means many more women may be suitable for the combined procedure.”

Related Links:
UCL


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.